Aclaris Therapeutics, Inc. (33)

Browse by Contract Category

Contracts

Seventh Amended and Restated Non-Employee Director Compensation Policy (Filed With SEC on February 24, 2022)
Underwriting Agreement by and among Aclaris Therapeutics, Inc., Jefferies LLC, SVB Leerink LLC and Piper Sandler & Co., dated June 9, 2021 (Filed With SEC on June 11, 2021)
Sales Agreement, dated May 20, 2021, by and among Aclaris Therapeutics, Inc., SVB Leerink LLC and Cantor Fitzgerald & Co (Filed With SEC on May 20, 2021)
Description of Securities (Filed With SEC on February 25, 2021)
Second Amendment to Sublease, dated as of April 29, 2020, by and between the Registrant and Auxilium Pharmaceuticals, LLC (Filed With SEC on May 7, 2020)
Severance Agreement and General Release, dated as of January 7, 2022, by and between the Registrant and David Gordon (Filed With SEC on February 24, 2022)
Severance Agreement and General Release, dated as of November 1, 2021, by and between the Registrant and Kamil Ali-Jackson (Filed With SEC on February 24, 2022)
Employment Agreement, dated as of January 31, 2022, by and between the Registrant and James Loerop (Filed With SEC on February 24, 2022)
Employment Agreement, dated as of January 12, 2022, by and between the Registrant and Joseph Monahan (Filed With SEC on February 24, 2022)
Sixth Amended and Restated Non-Employee Director Compensation Policy (Filed With SEC on February 24, 2022)
Amended and Restated Employment Agreement, dated as of January 12, 2022, by and between the Company and Frank Ruffo (Filed With SEC on January 14, 2022)
Amended and Restated Employment Agreement, dated as of January 12, 2022, by and between the Company and Neal Walker (Filed With SEC on January 14, 2022)
Fifth Amended and Restated Non-Employee Director Compensation Policy (Filed With SEC on August 5, 2021)
Change in Control Severance Benefit Plan, effective January 1, 2017, as amended by First Amendment to Change in Control Severance Benefit Plan, effective October 2, 2019 (Filed With SEC on February 25, 2021)
Fourth Amended and Restated Non-Employee Director Compensation Policy (Filed With SEC on February 25, 2021)
Underwriting Agreement by and among Aclaris Therapeutics, Inc., Cantor Fitzgerald & Co. and William Blair & Company, L.L.C., dated January 20, 2021 (Filed With SEC on January 22, 2021)
Registration Rights Agreement, dated as of August 13, 2020, by and between the Company and Lincoln Park (Filed With SEC on August 13, 2020)
Purchase Agreement, dated as of August 13, 2020, by and between the Company and Lincoln Park (Filed With SEC on August 13, 2020)
First Amendment to Clinical and Commercial Supply Agreement, dated as of June 12, 2020, by and between the Registrant and PeroxyChem LLC (Filed With SEC on August 7, 2020)
Warrant to Purchase Stock, issued to Silicon Valley Bank, dated as of March 30, 2020 (Filed With SEC on March 31, 2020)
Loan and Security Agreement, by and among the Company, Confluence Discovery Technologies, Inc. and Silicon Valley Bank, dated as of March 30, 2020 (Filed With SEC on March 31, 2020)
Open Market Sale Agreement, dated March 13, 2020, by and between Aclaris Therapeutics, Inc. and Jefferies LLC (Filed With SEC on March 13, 2020)
Employment Agreement with Frank Ruffo, dated as of September 17, 2015 (Filed With SEC on February 25, 2020)
Third Amended and Restated Non-Employee Director Compensation Policy (Filed With SEC on February 25, 2020)
Second Amended and Restated Non-Employee Director Compensation Policy (Filed With SEC on February 25, 2020)
Description of Securities (Filed With SEC on February 25, 2020)
First Amendment to License and Collaboration Agreement, by and between the Company and Rigel Pharmaceuticals, Inc. dated as of October 15, 2019 (Filed With SEC on October 17, 2019)
Asset Purchase Agreement, by and between the Company and EPI Health, LLC, dated as of October 10, 2019 (Filed With SEC on October 11, 2019)
Form of Performance Restricted Stock Unit Grant Notice and Restricted Stock Unit Award Agreement used in connection with the 2015 Equity Incentive Plan (Filed With SEC on March 18, 2019)
Loan and Security Agreement, dated as of October 15, 2018, by and among Oxford Finance LLC, the lenders party thereto, the Registrant, Confluence Discovery Technologies, Inc. and... (Filed With SEC on March 18, 2019)
First Amendment to Sublease, dated as of December 13, 2017, by and between the Registrant and Auxilium Pharmaceuticals, LLC (Filed With SEC on March 18, 2019)
Amended & Restated Non-Employee Director Compensation Policy (Filed With SEC on March 18, 2019)
Form of Performance Stock Option Grant Notice and Stock Option Agreement used in connection with the 2015 Equity Incentive Plan (Filed With SEC on March 18, 2019)